

ASX Announcement


16 April 2026

Q3 Sales rise by over 300% to \$8.3m

16 April 2026. Sydney, Australia. Xenitra Limited (ASX:XEN) (the “Company”) informs shareholders that sales have risen materially in Q3 compared to Q2 and have grown strongly over the quarter.

Xenitra is pioneering a dynamic blockchain tokenised sales ecosystem in Asia, specialised in fast-moving consumer goods (“FMCG”), nutraceuticals and OTC Medicine products that are sold through established distribution channels spanning Business-to-Business (B2B) wholesale, retail distribution and all major ecommerce platforms in Asia with sales of more than \$70m since 2024.

Sales in Q3 have risen by more than 300% vs Q2 to \$8.3m (preliminary unaudited) driven by the Nutritionals business that now includes the recently announced \$30m strategic partnership with Rockcheck Group for Danone products.



For personal use only

Chairman, Anthony Noble said:

"The Company saw a strong growth in sales accross the quarter with sales in March surpassing \$4m AUD, representing an almost full recovery the annualised sales levels of FY24, after a year of business restructuring and turnaround. This result was achieved with a leaner and more focussed structure. While driving these results in the quarter, the Company has also launched two new and higher margin sales channels, OTC Medicines and the Blockchain Tokenised sales. These two new divisions, represent completely new sources of future revenue growth, with significantly higher gross margins. The value of this work is not reflected in this strong performance in Q3, but will begin to deliver sales in Q4. Importantly, the Company also cemented a solid floor to revenue in the Nutritionals division for the coming year, with the signing of the \$30m Rockcheck offtake agreement for Danone products. This important customer also approved Xenitra as a supplier to the conglomerate more broadly, which enables the sales of further products that will also be accretive to revenues.

"After a period of transition and renewal, the Company now has a solid basis from which to grow accross multiple new markets, all of which are firmly alligned to our strategy and are based in markets where the Company has a proven track record for sales and marketing excellence. The aquisition of Fukang has put in place the required team and an established online presence for the new OTC medicines division while the launch of OPAL token initiated our blockchain tokenised, Web3 sales ecoystem – a truly ground breaking and innovative new division in the Company, anchored in real world assets, that are a class of products that the Company is highly experienced in selling into our diverse and deep distribution channels."

This release has been approved by the board of directors.

About Xenitra Limited

Xenitra specialises in fast-moving consumer goods (FMCG), nutraceuticals and over-the-counter (OTC) medicine and personal care products that are sold through a channel optimised sales ecosystem including distribution channels spanning Business-to-Business (B2B) trading, retail distribution and all

For personal use only

major ecommerce platforms in China. Xenitra is an established brand acceleration partner for western brands entering the Asian markets. Through our proprietary platform, we have a proven track record of delivering exceptional market integration, providing marketing insights and delivering sales velocity.

Forward Looking Statements

This announcement may contain forward-looking statements, including statements regarding: plans, strategies and objectives of management; anticipated revenue, products, and stores; operating costs; Chinese tourism; Governmental policies and preferences (both Australian and Chinese). Forward-looking statements can be identified by the use of terminology such as 'intend', 'aim', 'project', 'anticipate', 'estimate', 'plan', 'believe', 'expect', 'may', 'should', 'will', 'continue', 'annualised' or similar words. These statements discuss future expectations concerning the results of operations or financial condition, or condition or provide other forward-looking statements. These forward-looking statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. Readers are cautioned not to put undue reliance on forward-looking statements. Except as required by applicable regulations or by law, the Group does not undertake any obligation to publicly update or review any forward-looking statements, whether as a result of new information or future events. Past performance cannot be relied on as a guide to future performance.